Location History:
- Zhejiang, CN (2016 - 2017)
- Taizhou, CN (2014 - 2018)
Company Filing History:
Years Active: 2014-2018
Title: Zhenliang Chen: Innovator in Photodynamic Therapy
Introduction
Zhenliang Chen is a prominent inventor based in Taizhou, China, known for his significant contributions to the field of photodynamic therapy. With a total of four patents to his name, Chen has focused on developing innovative solutions for cancer treatment, particularly through the use of targeted therapies.
Latest Patents
Chen's latest patents include a targeting thymidine kinase photosensitizer and pharmaceutical composition aimed at enhancing cancer treatment. This invention improves the selectivity of photosensitizers to tumor cells, allowing for better tolerance and achieving maximum blood concentration within 24 hours. The technology features a larger conjugated system and a longer absorption wavelength, making photodynamic therapy (PDT) more practical and economical. Additionally, the targeting thymidine kinase photosensitizer can be utilized for both diagnosis and treatment of prostatic carcinoma, guided by fluorescence imaging. Another notable patent involves a cyanine dye compound and its preparation method, which enhances the accuracy of dye-tumor cell combinations while minimizing liver residue. This dual-function agent for photodynamic therapy significantly improves tumor absorption of the conjugates.
Career Highlights
Zhenliang Chen is currently associated with Zhejiang Hisun Pharmaceutical Co., Ltd., where he continues to innovate in the pharmaceutical field. His work has been instrumental in advancing cancer treatment methodologies, particularly through the integration of photodynamic therapy.
Collaborations
Chen collaborates with notable colleagues, including Hua Bai and Ravindra Kumar Pandey, contributing to a dynamic research environment that fosters innovation and development in cancer therapies.
Conclusion
Zhenliang Chen's work exemplifies the intersection of innovation and healthcare, particularly in the realm of cancer treatment. His patents reflect a commitment to improving therapeutic outcomes and enhancing the efficacy of existing treatment modalities.